Multiple sclerosis (MS) is the leading cause of neurological disability in young adults.
Introduction
Multiple sclerosis (MS) is the leading cause of neurological disability in young adults [1] .
Since the pathophysiology of MS is characterized by dissemination in space, as well as in time, the autonomic nervous system is inevitably damaged in the course of the disease in many patients and the proportion of affected patients increases with disease duration [2] .
Activity of the disease seems to affect the parasympathetic and sympathetic parts of the autonomic system in different patterns. While long-term disease activity leads to sympathetic dysfunction, parasympathetic dysfunction correlates with progression of clinical disability [3] . Autonomic dysfunction (AD) in MS is explained by presence of lesions in regions responsible for autonomic regulation, such as nuclei in the periventricular region of fourth ventricle in the brainstem as well as medullar lesions [4, 5] . The total MRI brain MS lesion load is another pathologic substrate related to AD incidence as demonstrated by Saari et al [6] . On the other hand, AD has been related to MRI findings of cervical spinal cord atrophy rather than the presence of demyelinating lesions in that region, postulating that AD results not solely from demyelination but from axonal loss as well [7] .
Reports about frequency of AD in MS patients vary notably between groups.
Nevertheless its impact on quality of life is substantial but, unfortunately, often overlooked. This is evident in scores used to assess neurological disability for clinical and research purposes such as the Kurtzke Expanded disability status scale (EDSS) where AD is underappreciated being represented with only bowel and bladder dysfunction.
The aim of this article is to present a concise review of various symptoms and signs of autonomic system dysfunction in MS.
Cardiovascular dysfunction
Cardiovascular autonomic dysfunction is reported to be present in up to two-thirds of MS patients and is known to show deterioration during the course of the disease [8, 9] .
Orthostatic intolerance occurs in up to 50% of MS patients [10] . It is characterized by symptoms such as dizziness, nausea and palpitations when assuming upright position or prolonged standing or sitting. Head up tilt table testing is a valuable diagnostic method used for assessment of impaired heart rate and blood pressure response to orthostatic challenge. Our group has observed a substantial number of MS patients with a variety of pathologic tilt table test results, such as orthostatic hypotension (OH) (Fig. 1) or postural orthostatic tachycardia syndrome (POTS) (Fig. 2) [11] . OH represents a significant and sustained decrease of blood pressure upon standing [12] . MS patients have a greater tendency to develop OH because of impaired sympathetic vasoconstrictory reflex responsible for maintaining adequate blood pressure after standing up from a supine position, lack of which causes subsequent pooling of blood into lower extremities [13] .
POTS is characterized by sustained heart rate increase on orthostatic challenge without concomitant OH and is associated with symptoms of orthostatic intolerance [14] . POTS has been reported to occur frequently in MS and the connection of the two entities is explained by the presence of demyelinating brainstem and hemispheral lesions disrupting the physiological heart rate variability modulation [10, 14] . Almost half of POTS patients complain of fatigue and the concomitant appearance of POTS and MS aggravates the dire sense of fatigue that MS patients often experience [15] .
There is a battery of other clinical tests commonly used to assess cardiac autonomic dysfunction such as deep breathing test and Valsalva maneuver. Sanya et al. used baroreflex stimulation to demonstrate that MS patients have impairment of both the vagal mediated heart rate variability, as well as sympathetic control of blood vessel tone [16] .
An interesting hypothesis was postulated by Keselbrener et al. who found that age-related reduction in vagal activity occurred earlier in MS patients complaining of fatigue, assuming that this form of AD may well be the pathological cause of fatigue [17] .
It is important to bear in mind that de novo appearance of cardiac symptoms in MS can actually be a sign of disease exacerbation. Acute central nervous system lesions can induce an increased release of catecholamines causing necrotic changes in cardiac myocytes [18] . This, in return, can disrupt the endocardial conduction system causing arrhythmias such as sinus bradycardia or paroxysmal atrial fibrillation [19, 20] . There have even been reports of cardiogenic shock and pulmonary edema caused by MS relapse [21, 22] . Although the catecholamine surge in acute brain lesions can lead to myocardial damage, such as demonstrated in Takotsubo syndrome, there is, as well, an association presence of demyelinating lesions in the brainstem and the disruption of central autonomic influence on cardiac and respiratory system [22, 23] . MS therapy itself can contribute or cause cardiac pathology. Administration of high doses of corticosteroids to patients in relapse has been known to cause cardiac arrhythmias [24] . Mitoxantrone is occasionally used in patients that don't respond favorably to immunomodulating therapy.
It is a drug with potential cardiotoxic effect and should therefore be administered with caution [25] . Unfortunately, some of the newer immunomodulatory drugs have cardiac side effects as well. Fingolimod treatment initiation must be accompanied with cardiac monitoring since sinus bradycardia, as well as asistoly, has ocurrred following its administration [26, 27] .
The initial therapy of orthostatic intolerance is consisted of patient education, reassurance and administration of counter-pressure maneuvers [28] . The next step is pharmacological intervention with volume expanders, vasoconstrictors and adrenergic antagonists. Patients with cardiac arrhythmia or ventricular dysfunction should be treated in consultation with a cardiology specialist. A novel cardiac symptom in an MS patient without a history of heart disease should always raise suspicion of MS relapse and be treated accordingly.
Bladder dysfunction
Urinary symptoms can be present as either storage phase dysfunction leading to incontinence or voiding phase dysfunction resulting in retention and incomplete bladder emptying [29] . These symptoms occur in up to 97% of MS patients during the course of the disease [30] . Incontinence often leads to social embarrassment and can have a severe impact on quality of life. The economic burden it produces is not to be depreciated [31] .
Bladder dysfunction in MS results mainly from demyelinating lesions affecting the spinal cord, interrupting neural connections from the pontine micturition center to the parasympathetic sacral micturition center [32] . This leads to sensitization of the so-called silent C fibers causing detrusor hyperactivity, the most common problem in MS patients [33] . This was corroborated by urodynamic studies, which found detrusor hyperreflexia to be the main abnormality present, followed by detrusor sphincter dyssinergia and the least number of MS patients showing detrusor hyporeflexia [34] . The most common urinary symptom reported from the same group of patients was urgency followed by frequency, urge incontinence, stress incontinence and dysuria [34] .
Storage and voiding symptoms can be reduced in female patients by pelvic floor muscle training [35] . Suprapubic vibration and Crede manouever can be given a trial in patients with incomplete bladder emptying [36] . Pharmacological treatment of detrusor hyperreflexia is based on anticholinergics such as oxybutynin, which reduce detrusor activity. Intranasal desmopressin is applicated to decreases the number of voiding episodes and Botulinum toxin A injected intravesically has shown to be an efficient therapy for bladder overactivity [37, 38, 39] . Urinary retention and incomplete bladder emptying may lead to hydronephrosis and chronic renal failure. Therefore the residual urine volume should be always measured. If there is a raised post-micturition residual urinary volume, the most efficient, but incommodious therapy, is intermittent selfcatheterization [30] . α blockers can be used if the residual volume is not substantial but [43] . Antibiotics should be administered when the infection's symptomatic. As far as prevention of urinary infection is concerned, prophylactic administration of antibiotics doesn't reduce clinical evident UTI but decreases the number of asymptomatic bacteriuria [44] .
Sexual dysfunction
More than 80% of MS patients report sexual dysfunction (SD) [45] . Patients should be reassured to talk freely about this intimate subject, as SD often happens to be overlooked or underestimated as a symptom and therefore denied the possibility of treatment. The pathogenesis of SD in MS might be the result of lesions disrupting the hypothalamicpituitary-adrenal and the hypothalamic-pituitary-gonadal axis [46] . There is, as well, an association between the presence of sphinteric disorders and some symptoms of SD [47, 48] . Relapse of the disease itself doesn't seem to add to the number of SD symptoms [49] . Most of the affected patients experience sexual hypoactivitiy [50] . Beside reduced libido, men are often disabled by erectile dysfunction and premature ejaculation whereas women experience reduced libido, decreased vaginal lubrication and difficulties in reaching orgasm [45] . This all contributes to MS patients having sexual intercourse less frequently compared to patients with other chronic diseases or healthy controls [47] . This is an important factor adding to relationship dissatisfaction felt by MS patients, as well as their partners [50] . Conceivably, there seems to be an association between cognition and impaired sexuality as patients with SD more often report symptoms such as memory and concentration problems [48] .
Sildenafil, an oral phosphodiesterase-5 inhibitor, is an effective agent for erectile dysfunction in men but has been of limited usefulness in women, showing only some improvement in the lubrication domain [51, 52] . Another agent used for erectile dysfunction is apomorphine hydrochloride administered sublingually [53] . In women, hormonal therapy such as estrogen and methyltestosterone may be used to improve lack of libido and vaginal dryness [53] . Increased partner support has a positive effect on sexual satisfaction in MS patients stressing the importance of psychosocial interventions and couple support therapy [54] .
Bowel dysfunction
Constipation is present in 43% of MS patients while fecal incontinence affects 51% of patients [55] . All together, 68% of MS population complains of bowel dysfunction symptoms [55] . Constipation is a result of not only disease exacerbation itself, but also of decreased ambulation of patients and concomitant medications that may alter bowel movement. As well, there is evidence of paradoxical puborectalis contraction in MS, corresponding to detrusor sphincter dyssinergia in patients with bladder symptoms [56] .
Fecal incontinence results from impairment of external anal sphincter function [57] .
Gastric emptying scintigraphy can be used to assess autonomic dysfunction of the gastrointestinal tract. MS patients tend to have slower gastric emptying rate, which is associated with symptoms such as sense of fullness, hiccups, vomiting and gastroesophageal reflux [58] .
Constipation treatment is based on laxatives and diet rich in fibers wit a high fluid intake [59] . Treatment of fecal incontinence is often unsatisfactory and relies on combining antimotility agents with rectal stimulants [32] . Transanal irrigation has mainly been used to treat symptoms in neurogenic bowel syndrome. A recent study has demonstrated its effectiveness in MS, with incontinence showing greater improvement than constipation [60] . Biofeedback behavioral therapy can lead to improvement of resistant bowel symptoms and alleviate depression associated with this type of symptoms [61] .
Sleep disorders
Many MS patients report sleeping-related difficulties. In a large study of more than thousand individuals with MS, prevalence of moderate or severe sleep problems was more than 50% [62] . The most common symptoms are difficulty initiating and maintaining sleep, frequent awakenings because of leg cramps and discomfort, snoring and nocturia [63] . Lack of sleep leads to increased fatigue, daytime somnolence and respiratory dysfunction episodes [64] . Involvement of hypothalamus on MRI is associated with increased fatigue [65] . There has been a report of hypersomnia and low orexin-1 level due to a demyelinating lesion in the hypothalamus [66] . However, studies in larger groups of patients with relapsing remitting MS have found cerebrospinal fluid levels of hypocretin-1 to be normal, and they didn't observe a correlation with hypersomnolence [67] . Many of the drugs used in MS treatment, including immunomodulatory therapy, can cause dyssomnias [68] . Nocturnal polysomnography is the method of choice for analyzing the pattern of sleep and identifying the type of disorder. It is important to stress out that depression is strongly associated with sleep disorders and that their treatment should be considered concomitantly [69] .
Treatment of insomnias is pharmacologically based on short-term use of agents such as antihistaminics, benzodiazepines and sedating antidepressants with education on sleep hygiene, relaxation technics and behavioral therapy [70] . Other treatable entities that contribute to sleep problems such as pain, leg cramps and nocturia should be properly managed [62, 69] . Treatment of sleep disorder results in improvement not only of patient's sleepiness, but of feeling of fatigue, energy and well being [71] .
Sudomotor dysfunction
Heat or increased ambient temperature is one of the most common factors known to worsen MS symptoms [72] . Sweating, the physiological response to heat is mediated by sympathetic activity. Decreased sudomotor response occurs significantly higher in MS patients than in healthy controls and is related to disease activity [73] . Thermoregulation is impaired in MS patients because of interruption in the central sudomotor pathways that originate in the preoptic region of the hypothalamus and descend to intermediolateral column of the spinal cord where they exit the central nervous system and travel to sweat glands via peripheral nerves [74] . Temperature increase can diminish the current needed for depolarization of axons [75] . Thus, hyperthermia can cause a neuro-blockade of partially demyelinated axons, which leads to neurologic deterioration known as Uhthoff's phenomenon [76] . Since there have been reports that such deterioration can be longlasting, difficulties in thermoregulation may have a more serious influence on patients than previously suspected [77] . Head and neck cooling reduce body temperature and may provide alleviation of heat-induced symptoms in MS [78] . Avoidance of prolonged exposure to heat is recommended to all MS patients.
Conclusion
Virtually any part of the diverse autonomic system can be affected in MS, causing beats/minute, without fall in blood pressure.
